- Home
- ACLX
ACLX
Arcellx Inc.
as 07-26-2024 4:00pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.4B | IPO Year: | 2022 |
| Target Price: | $76.67 | AVG Volume (30 days): | 463.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.88 - $75.10 | Next Earning Date: | 08-12-2024 |
| Revenue: | $131,663,000 | Revenue Growth: | 635.05% |
| Revenue Growth (this year): | 10.2% | Revenue Growth (next year): | -3.27% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jul 16 '24 | Sell | $65.30 | 10,901 | $711,853.83 | 9,278 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jul 1 '24 | Sell | $56.20 | 2,783 | $156,390.69 | 9,278 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jul 1 '24 | Sell | $55.26 | 17,217 | $951,371.82 | 12,061 | SEC Form 4 |
| Patel Kavita | ACLX | Director | Jun 27 '24 | Sell | $54.51 | 5,029 | $274,108.66 | 0 | SEC Form 4 |
| Patel Kavita | ACLX | Director | Jun 27 '24 | Sell | $54.02 | 4,971 | $268,547.84 | 5,029 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jun 12 '24 | Sell | $56.03 | 82 | $4,594.74 | 9,278 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jun 12 '24 | Sell | $55.13 | 19,918 | $1,098,073.36 | 9,360 | SEC Form 4 |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | May 23 '24 | Sell | $50.71 | 12,121 | $614,655.91 | 19,792 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $50.99 | 7,087 | $361,345.58 | 20,019 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $51.48 | 10,481 | $539,541.97 | 9,538 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $52.63 | 500 | $26,314.00 | 9,038 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $53.55 | 100 | $5,355.00 | 8,938 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Apr 16 '24 | Sell | $55.36 | 6,790 | $375,906.62 | 2,612 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Apr 16 '24 | Sell | $56.03 | 2,612 | $146,352.97 | 0 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Apr 1 '24 | Sell | $66.67 | 14,919 | $994,679.57 | 77,420 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Apr 1 '24 | Sell | $67.58 | 5,456 | $368,731.21 | 71,964 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Apr 1 '24 | Sell | $68.42 | 2,711 | $185,476.05 | 69,253 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $69.59 | 10,057 | $699,910.88 | 40,246 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $70.13 | 25,975 | $1,821,696.88 | 14,271 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $71.36 | 4,333 | $309,210.68 | 9,938 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $72.25 | 1,000 | $72,247.40 | 8,938 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $68.55 | 2,555 | $175,138.35 | 11,833 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $69.36 | 2,034 | $141,079.05 | 9,799 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Mar 22 '24 | Sell | $70.19 | 861 | $60,430.66 | 8,938 | SEC Form 4 |
| Carroll Jill | ACLX | Director | Mar 21 '24 | Sell | $70.55 | 504,263 | $35,575,754.65 | 1,479,148 | SEC Form 4 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
GuruFocus.com
a month ago
Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX)
Simply Wall St.
a month ago
We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth
Investor's Business Daily
a month ago
Arcellx Stock Earns Relative Strength Rating Upgrade
MT Newswires
a month ago
Arcellx Insider Sold Shares Worth $1,102,668, According to a Recent SEC Filing
MT Newswires
2 months ago
Piper Sandler Starts Arcellx With Overweight Rating, $70 Price Target
GuruFocus.com
2 months ago
Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX)
MT Newswires
2 months ago
Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating
MT Newswires
2 months ago
Evercore ISI Starts Arcellx With Outperform Rating
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.